Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN versus ERYC 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN versus ERYC 125.
E-MYCIN vs ERYC 125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
250-500 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in severe hepatic impairment; no significant change in renal impairment due to minimal renal clearance.
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Primarily hepatic metabolism and biliary excretion with significant enterohepatic circulation; approximately 2-15% excreted unchanged in urine; 10-40% excreted in feces via bile; less than 1% eliminated as unchanged drug in feces from unabsorbed drug.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic